


Supplementary figure S1 Patient disposition



Primary reasons for discontinuation were indicated in the figure.

Supplementary table S1 Serious adverse events

Treatment	Sex/Age	Event	Relationship to study drug
Placebo	Female/71	Atrial fibrillation	Not related
		Cardiac failure	Not related
		Hepatic function abnormal	Not related
Peficitinib 25mg QD	Female/42	Abortion spontaneous	Related
Peficitinib 50mg QD	Female/60	Death due to cerebral haemorrhage	Not related
	Male/59	Rheumatoid arthritis	Not related
Peficitinib 100mg QD	Male/67	*Cholecystitis	Related
	Female/53	Femoral neck fracture	Not related
		Femoral neck fracture	Not related
	Female/63	Rheumatoid arthritis	Not related


*The event was categorized as hepatobiliary disorders (System Organ Class in MedDRA v11.1).

Supplementary table S2 Treatment-emergent adverse events >5% in any group

System Organ Class Preferred Term	Placebo (N=56)	Peficitinib 25mg QD (N=55)	Peficitinib 50mg QD (N=57)	Peficitinib 100mg QD (N=55)	Peficitinib 150mg QD (N=58)
Overall	36 (64.3%)	39 (70.9%)	37 (64.9%)	29 (52.7%)	39 (67.2%)
Infections and infestations	12 (21.4%)	18 (32.7%)	14 (24.6%)	7 (12.7%)	17 (29.3%)
Nasopharyngitis	3 (5.4%)	11 (20.0%)	9 (15.8%)	1 (1.8%)	9 (15.5%)
Cystitis	3 (5.4%)	1 (1.8%)	2 (3.5%)	0 (0.0%)	2 (3.4%)
Gastrointestinal disorders	3 (5.4%)	8 (14.5%)	11 (19.3%)	6 (10.9%)	10 (17.2%)
Diarrhoea	1 (1.8%)	4 (7.3%)	1 (1.8%)	1 (1.8%)	2 (3.4%)
Constipation	0 (0.0%)	1 (1.8%)	1 (1.8%)	3 (5.5%)	0 (0.0%)
Dyspepsia	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (5.2%)
Stomatitis	1 (1.8%)	0 (0.0%)	3 (5.3%)	0 (0.0%)	0 (0.0%)
Musculoskeletal and connective tissue disorders	21 (37.5%)	12 (21.8%)	12 (21.1%)	6 (10.9%)	5 (8.6%)
Rheumatoid arthritis	18 (32.1%)	12 (21.8%)	8 (14.0%)	4 (7.3%)	4 (6.9%)
Investigations	2 (3.6%)	7 (12.7%)	1 (1.8%)	6 (10.9%)	13 (22.4%)
CPK increased	0 (0.0%)	2 (3.6%)	1 (1.8%)	1 (1.8%)	7 (12.1%)
TG increased	0 (0.0%)	3 (5.5%)	0 (0.0%)	2 (3.6%)	1 (1.7%)
Lipids increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (5.2%)

Supplementary figure S2

Mean Change from Baseline in MMP-3 at Week12/Early termination



Statistical comparison wasn't performed.